Department of Radiology, Washington University, St. Louis, Missouri 63110, USA.
J Nucl Med. 2013 Jul;54(7):1135-41. doi: 10.2967/jnumed.112.114777. Epub 2013 May 8.
Atherosclerosis is the pathophysiologic process behind lethal cardiovascular diseases. It is a chronic inflammatory progression. Chemokines can strongly affect the initiation and progression of atherosclerosis by controlling the trafficking of inflammatory cells in vivo through interaction with their receptors. Some chemokine receptors have been reported to play an important role in plaque development and stability. However, the diagnostic potential of chemokine receptors has not yet been explored. The purpose of this study was to develop a positron emitter-radiolabeled probe to image the upregulation of chemokine receptor in a wire-injury-accelerated apolipoprotein E knockout (ApoE(-/-)) mouse model of atherosclerosis.
A viral macrophage inflammatory protein II (vMIP-II) was used to image the upregulation of multiple chemokine receptors through conjugation with DOTA for (64)Cu radiolabeling and PET. Imaging studies were performed at 2 and 4 wk after injury in both wire-injured ApoE(-/-) and wild-type C57BL/6 mice. Competitive PET blocking studies with nonradiolabeled vMIP-II were performed to confirm the imaging specificity. Specific PET blocking with individual chemokine receptor antagonists was also performed to verify the upregulation of a particular chemokine receptor. In contrast, (18)F-FDG PET imaging was performed in both models to evaluate tracer uptake. Immunohistochemistry on the injury and sham tissues was performed to assess the upregulation of chemokine receptors.
(15)O-CO PET showed decreased blood volume in the femoral artery after the injury. (64)Cu-DOTA-vMIP-II exhibited fast in vivo pharmacokinetics with major renal clearance. PET images showed specific accumulation around the injury site, with consistent expression during the study period. Quantitative analysis of tracer uptake at the injury lesion in the ApoE(-/-) model showed a 3-fold increase over the sham-operated site and the sites in the injured wild-type mouse. (18)F-FDG PET showed significantly less tracer accumulation than (64)Cu-DOTA-vMIP-II, with no difference observed between injury and sham sites. PET blocking studies identified chemokine receptor-mediated (64)Cu-DOTA-vMIP-II uptake and verified the presence of 8 chemokine receptors, and this finding was confirmed by immunohistochemistry.
(64)Cu-DOTA-vMIP-II was proven a sensitive and useful PET imaging probe for the detection of 8 up-regulated chemokine receptors in a model of injury-accelerated atherosclerosis.
利用病毒巨噬细胞炎性蛋白 II(vMIP-II)与 DOTA 缀合以进行(64)Cu 放射性标记,并进行 PET 成像,从而构建一种正电子发射体放射性标记的探针来检测动脉粥样硬化损伤加速的载脂蛋白 E 敲除(ApoE(-/-))小鼠模型中趋化因子受体的上调。
在血管损伤后的 2 和 4 周,对血管损伤的 ApoE(-/-)和野生型 C57BL/6 小鼠进行成像研究。用未放射性标记的 vMIP-II 进行竞争 PET 阻断研究以确认成像的特异性。还进行了针对各个趋化因子受体拮抗剂的特定 PET 阻断以验证特定趋化因子受体的上调。相比之下,在两种模型中都进行了(18)F-FDG PET 成像以评估示踪剂摄取。对损伤和假手术组织进行免疫组织化学分析以评估趋化因子受体的上调。
(15)O-CO PET 显示损伤后的股动脉血流减少。(64)Cu-DOTA-vMIP-II 表现出快速的体内药代动力学特性,主要通过肾脏清除。PET 图像显示在损伤部位周围有特异性聚集,在整个研究期间都有一致的表达。在 ApoE(-/-)模型中,损伤病变处示踪剂摄取的定量分析显示,与假手术部位和损伤野生型小鼠的部位相比,增加了 3 倍。(18)F-FDG PET 显示的示踪剂摄取明显少于(64)Cu-DOTA-vMIP-II,损伤部位与假手术部位之间没有差异。PET 阻断研究确定了趋化因子受体介导的(64)Cu-DOTA-vMIP-II 摄取,并验证了 8 种趋化因子受体的存在,这一发现通过免疫组织化学得到了证实。
(64)Cu-DOTA-vMIP-II 是一种灵敏且有用的 PET 成像探针,可用于检测损伤加速动脉粥样硬化模型中 8 种上调的趋化因子受体。